Maximizing the clinical utility of antimüllerian hormone testing in women's health

Current Opinion in Obstetrics and Gynecology

Volumn 26, Issue 4, 2014, Pages 226-236

  Leader, Benjamin ^a   Baker, Valerie L ^b  

^a Clinical Research Division   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMH; Menopause; Ovarian reserve; Polycystic ovarian syndrome; Premature ovarian failure

Indexed keywords

BIOLOGICAL MARKER; METHOTREXATE; MUELLERIAN INHIBITING FACTOR; PRASTERONE;

AUTOIMMUNITY; BIRTH RATE; CALIBRATION; CLINICAL DECISION MAKING; ENDOMETRIOSIS; GRANULOSA CELL TUMOR; HIGH RISK POPULATION; HORMONAL CONTRACEPTION; HORMONE BLOOD LEVEL; HUMAN; LIVE BIRTH; MEASUREMENT ACCURACY; MENOPAUSE; MONITORING; OVARIAN FUNCTION TEST; OVARY POLYCYSTIC DISEASE; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; BLOOD; DECISION SUPPORT SYSTEM; FEMALE; OVARY DISEASE; OVULATION INDUCTION; PREDICTIVE VALUE; PROCEDURES; WOMEN'S HEALTH;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MENOPAUSE; OVARIAN DISEASES; OVULATION INDUCTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; WOMEN'S HEALTH;

EID: 84904068270     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000087     Document Type: Review

References (113)

1. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-mullerian hormone in women. Hum Reprod Update 2014; 20:370-385.
2. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013; 99:963-969.
3. Leader B, Baker V. A practical approach to recent advances in ovarian reserve resting. In: Sch legel PN, Fauser BC, Carrell DT, Racowsky C, editors. Biennial reviews of infertility, 3rd ed. New York: Springer Science + Business media; 2013.
4. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2012; 98:1407-1415.
5. Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013; 19:519-527.
6. Grynberg M, Pierre A, Rey R, et al. Differential regulation of ovarian antimullerian hormone (AMH) by estradiol through alpha- and beta-estrogen receptors. J Clin Endocrinol Metab 2012; 97:E1649-E1657.
7. Mehta BN, Chimote MN, Chimote NN, et al. Follicular-fluid anti-mullerian hormone (FF AMH) is a plausible biochemical indicator of functional viability of oocyte in conventional in vitro fertilization (IVF) cycles. J Hum Reprod Sci 2013; 6:99-105.
8. La Marca A, Spada E, Grisendi V, et al. Normal serum anti-mullerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol 2012; 163:180-184.
9. Nelson SM, Iliodromiti S, Fleming R, et al. Reference range for the antimullerian hormone Generation II assay: a population study of 10 984 women, with comparison to the established Diagnostics Systems Laboratory nomogram. Fertil Steril 2014; 101:523?529.
10. Nelson SM, Messow MC, Wallace AM, et al. Nomogram for the decline in serum ntimullerian hormone: a population study of 9601 infertility patients. Fertil Steril 2011; 95:736-741; e1-e3.
11. Nelson SM, Messow MC, McConnachie A, et al. External validation of nomogram for the decline in serum anti-mullerian hormone in women: a population study of 15 834 infertility patients. Reprod Biomed Online 2011; 23:204-206.
12. Leader B, Hegde A, Baca Q, et al. High frequency of discordance between antimullerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5354 women in U.S. fertility centers. Fertil Steril 2012; 98:1037-1042.
13. Seifer DB, Baker VL, Leader B. Age-specific serum anti-mullerian hormone values for 17 120 women presenting to fertility centers within the United States. Fertil Steril 2011; 95:747-750.
14. Kelsey TW, Wright P, Scott M, et al. A validated model of serum anti-mullerian hormone from conception to menopause. PLoS One 2011; 6:e22024.
15. Lie Fong S, Visser JA, Welt CK, et al. Serum anti-mullerian hormone levels in healthy females: a nomogram ranging from infancy to adulthood. J Clin Endocrinol Metab 2012; 97:4650-4655.
16. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014; 20:124-140.
17. Lan VT, Linh NK, Tuong HM, et al. Anti-mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reprod Biomed Online 2013; 27:390-399.
18. Polyzos NP, Nelson SM, Stoop D, et al. Does the time interval between antimullerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. Fertil Steril 2013; 100:438-444.
19. Guzman L, Ortega-Hrepich C, Polyzos NP, et al. A prediction model to select PCOS patients suitable for IVM treatment based on antimullerian hormone and antral follicle count. Hum Reprod 2013; 28:1261-1266.
20. Weintraub A, Margalioth EJ, Chetrit AB, et al. The dynamics of serum anti-mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders. Eur J Obstet Gynecol Reprod Biol 2014; 176:163-167.
21. Aboulghar M, Saber W, Amin Y, et al. Impact of antimullerian hormone assays on the outcomes of in vitro fertilization: a prospective controlled study. Fertil Steril 2014; 101:134-137.
22. Brodin T, Hadziosmanovic N, Berglund L, et al. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab 2013; 98:1107-1114.
23. Pup LD, Zanet E, Rupolo M, et al. Which tools may help physicians in female fertility prediction after autologous bone marrow transplantation for lymphoma? A pilot study. J Chemother 2014; 1973947813Y0000000162.
24. Li HW, Lee VC, Lau EY, et al. Role of baseline antral follicle count and antimullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers. Gynecol Endocrinol 2014; 30:490-493.
25. Lehmann P, Velez MP, Saumet J, et al. Anti-mullerian hormone (AMH): a reliable biomarker of oocyte quality in IVF. J Assist Reprod Genet 2014; 31:493-498.
26. Merhi Z, Zapantis A, Berger DS, Jindal SK. Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve. J Assist Reprod Genet 2013; 30:1361-1365.
27. Lin WQ, Yao LN, Zhang DX, et al. The predictive value of anti-mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). J Assist Reprod Genet 2013; 30:649-655.
28. Himabindu Y, Gopinathan KK, Pandey AK, Sriharibabu M. Correlation of age and antimullerian hormone in assisted reproductive technology program outcome. Indian J Physiol Pharmacol 2013; 57:9-15.
29. Khader A, Lloyd SM, McConnachie A, et al. External validation of antimullerian hormone based prediction of live birth in assisted conception. J Ovarian Res 2013; 6:3.
30. Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of antimullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 2014; 20:560-570.
31. Kedem A, Haas J, Geva LL, et al. Ongoing pregnancy rates in women with low and extremely low AMH levels. A multivariate analysis of 769 cycles. PLoS One 2013; 8:e81629.
32. Streuli I, de Mouzon J, Paccolat C, et al. AMH concentration is not related to effective time to pregnancy in women who conceive naturally. Reprod Biomed Online 2014; 28:216-224.
33. Murto T, Bjuresten K, Landgren BM, Stavreus-Evers A. Predictive value of hormonal parameters for live birth in women with unexplained infertility and male infertility. Reprod Biol Endocrinol 2013; 11:61.
34. Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-mullerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab 2013; 98:3785-3792.
35. Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of Reproductive Aging Workshop +10 addressing the unfinished agenda of staging reproductive aging. Fertil Steril 2012; 97:843-851.
36. Dolleman M, Depmann M, Eijkemans MJ, et al. Anti-mullerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. Hum Reprod 2014; 29:584-591.
37. Ramezani Tehrani F, Dolleman M, van Disseldorp J, et al. Predicting menopausal age with anti-mullerian hormone: a cross-validation study of two existing models. Climacteric 2014; 10:1-8.
38. La Marca A, Sighinolfi G, Papaleo E, et al. Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. PLoS One 2013; 8:e57005.
39. Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in antimullerian hormone and ovarian reserve. Int J Endocrinol 2013; 2013: 818912.
40. Iino K, Tarakida A, Abe K, et al. Role of antimullerian hormone as a biomarker of the menopausal transition. Menopause 2013; 20:218-222.
41. Dolleman M, Faddy MJ, van Disseldorp J, et al. The relationship between antimullerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metab 2013; 98:1946-1953.
42. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013; 99:37-43.
43. Casadei L, Madrigale A, Puca F, et al. The role of serum anti-mullerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome. Gynecol Endocrinol 2013; 29:545-550.
44. Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet 2014; 31:213-220.
45. Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013; 28:1077-1083.
46. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013; 98:3332-3340.
47. Chao KC, Ho CH, Shyong WY, et al. Anti-mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J ChinMed Assoc 2012; 75:70-74.
48. Swellam M, Khaial A, Mosa T, et al. Antimullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI. Iran J Reprod Med 2013; 11:883-890.
49. Tian X, Ruan X, Mueck AO, et al. Anti-mullerian hormone levels in women with polycystic ovarian syndrome compared with normal women of reproductive age in China. Gynecol Endocrinol 2014; 30:126-129.
50. Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimullerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol 2014.
51. Sahmay S, Aydin Y, Atakul N, et al. Relation of antimullerian hormone with the clinical signs of hyperandrogenism and polycystic ovary morphology. Gynecol Endocrinol 2014; 30:130-134.
52. Baker VL. Primary ovarian insufficiency in the adolescent. Curr Opin Obstet Gynecol 2013; 25:375-381.
53. Kallio S, Aittomaki K, Piltonen T, et al. Anti-mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries. Hum Reprod 2012; 27:854-860.
54. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol 2012; 8:331-341.
55. Sahmay S, Usta TA, Erel T, et al. Elevated LH levels draw a stronger distinction than AMHin premature ovarian insufficiency. Climacteric 2014; 17:197-203.
56. Yoon SH, Choi YM, Hong MA, et al. Association study of anti-mullerian hormone and anti-mullerian hormone type II receptor polymorphisms with idiopathic primary ovarian insufficiency. Hum Reprod 2013; 28:3301-3305.
57. Spath MA, Feuth TB, Allen EG, et al. Intra-individual stability over time of standardized anti-mullerian hormone in FMR1 premutation carriers. Hum Reprod 2011; 26:2185?2191.
58. Gleicher N, Kim A, Barad DH, et al. FMR1-dependent variability of ovarian aging patterns is already apparent in young oocyte donors. Reprod Biol Endocrinol 2013; 11:80.
59. Gleicher N, Weghofer A, Kim A, Barad DH. The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve. PLoS One 2012; 7:e33638.
60. Gleicher N, Kim A, Weghofer A, Barad DH. Differences in ovarian aging patterns between races are associated with ovarian genotypes and subgenotypes of the FMR1 gene. Reprod Biol Endocrinol 2012; 10:77.
61. Gleicher N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet Gynecol Scand 2009; 88:1024-1030.
62. Choe SA, Kim KC, Lee JY, et al. The relationship between the number of CGG repeats and serum level of anti-mullerian hormone in women without FMR1 premutation. Eur J Obstet Gynecol Reprod Biol 2013; 169:275-278.
63. Kline JK, Kinney AM, Levin B, et al. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause 2014; 21:740-748.
64. La Marca A, Brozzetti A, Sighinolfi G, et al. Primary ovarian insufficiency: autoimmune causes. Curr Opin Obstet Gynecol 2010; 22:277-282.
65. Ma W, Zhan Z, Liang X, et al. Subclinical impairment of ovarian reserve in systemic lupus erythematosus patients with normal menstruation not using alkylating therapy. J Women's Health 2013; 22:1023-1027.
66. Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using antimullerian hormone. Lupus 2011; 20:1193-1197.
67. Senates E, Colak Y, Erdem ED, et al. Serum anti-mullerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. J Crohn's Colitis 2013; 7:e29-e34.
68. Chong YH, Campbell AJ, Farrand S, McLennan IS. Anti-mullerian hormone level in older women: detection of granulosa cell tumor recurrence. Int J Gynecol Cancer 2012; 22:1497-1499.
69. Mancaux A, Grardel Chambenoit E, Gagneur O, et al. [Granulosa cell tumor: difficulty of diagnosis and contribution of imaging]. Gynecol Obstet Fertil 2013; 41:439-445.
70. Carrarelli P, Rocha AL, Belmonte G, et al. Increased expression of antimullerian hormone and its receptor in endometriosis. Fertil Steril 2014; 101:1353-1358.
71. Muzii L, Luciano AA, Zupi E, Panici PB. Effect of surgery for endometrioma on ovarian function: a different point of view. J Minim Invasive Gynecol 2014.
72. Urman B, Alper E, Yakin K, et al. Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve. Reprod Biomed Online 2013; 27:212-216.
73. Alborzi S, Keramati P, Younesi M, et al. The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Fertil Steril 2014; 101:427-434.
74. Arthur R, Kachura J, Liu G, et al. Laparoscopic myomectomy versus uterine artery embolization: long-term impact on markers of ovarian reserve. J Obstet Gynaecol 2014; 36:240-247.
75. Jang WK, Lim SY, Park JC, et al. Surgical impact on serum anti-mullerian hormone in women with benign ovarian cyst: a prospective study. Obstet Gynecol Sci 2014; 57:121-127.
76. Pacchiarotti A, Frati P, Milazzo GN, et al. Evaluation of serum anti-mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis. Eur J Obstet Gynecol Reprod Biol 2014; 172:62-64.
77. Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril 2013; 99:477.e1-483.e1.
78. Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol 2014; 12:26.
79. Beneventi F, Locatelli E, Giorgiani G, et al. Gonadal and uterine function in female survivors treated by chemotherapy, radiotherapy, and/or bone marrow transplantation for childhood malignant and nonmalignant diseases. BJOG 2014; 121:856-865.
80. Ruddy KJ, O'Neill A, Miller KD, et al. Biomarker prediction of chemotherapyrelated amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat 2014; 144:591-597.
81. Hadji P, Kauka A, Ziller M, et al. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study. Breast Cancer Res Treat 2014; 144:343-351.
82. Henry NL, Xia R, Schott AF, et al. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 2014; 19:68-74.
83. Miyoshi Y, Ohta H, Namba N, et al. Low serum concentrations of antimullerian hormone are common in 53 female childhood cancer survivors. Hormone Res Paediatr 2013; 79:17-21.
84. Mok CC, Chan PT, To CH. Antimullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 2013; 65:206-210.
85. Kwon SK, Kim SH, Yun SC, et al. Decline of serum antimullerian hormone levels after laparoscopic ovarian cystectomy in endometrioma and other benign cysts: a prospective cohort study. Fertil Steril 2014; 101:435-441.
86. Ortega-Hrepich C, Polyzos NP, Anckaert E, et al. The effect of ovarian puncture on the endocrine profile of PCOS patients who undergo IVM. Reprod Biol Endocrinol 2014; 12:18.
87. Gleicher N, Kim A, Kushnir V, et al. Clinical relevance of combined FSH and AMH observations in infertile women. J Clin Endocrinol Metab 2013; 98:2136-2145.
88. Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013; 19:26-36.
89. Sowers M, McConnell D, Gast K, et al. Anti-mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 2010; 94:1482-1486.
90. Dorgan JF, Spittle CS, Egleston BL, et al. Assay reproducibility and withinperson variation of mullerian inhibiting substance. Fertil Steril 2010; 94:301-304.
91. Overbeek A, Broekmans FJ, Hehenkamp WJ, et al. Intra-cycle fluctuations of anti-mullerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012; 24:664-669.
92. Hadlow N, Longhurst K, McClements A, et al. Variation in antimullerian hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. Fertil Steril 2013; 99:1791-1797.
93. Van den Berg MH, van Dulmen-den Broeder E, Overbeek A, et al. Comparison of ovarian function markers in users of hormonal contraceptives during the hormone-free interval and subsequent natural early follicular phases. Hum Reprod 2010; 25:1520-1527.
94. Fabregues F, Castelo-Branco C, Carmona F, et al. The effect of different hormone therapies on antimullerian hormone serum levels in anovulatory women of reproductive age. Gynecol Endocrinol 2011; 27:216-224.
95. Deb S, Pincott-Allen CB, Clewes C, et al. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum antimüllerian hormone and small antral follicle count using three-dimensional ultr asound. Ultrasound Obstet Gynecol 2012; 39:574-580.
96. Mes-Krowinkel MG, Louwers YV, Mulders AG, et al. Influence of oral contraceptives on anthropomorphometric, endocrine, and metabolic profiles of anovulatory polycystic ovary syndrome patients. Fertil Steril 2014; 101: 1757-1765.
97. Kallio S, Puurunen J, Ruokonen A, et al. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril 2013; 99:1305-1310.
98. Koninger A, Kauth A, Schmidt B, et al. Anti-mullerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol 2013; 11:60.
99. Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-mullerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res 2013; 65:1534-1538.
100. Oriol B, Barrio A, Pacheco A, et al. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril 2008; 90:1579-1582.
101. Fouany MR, Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve? J Assist Reprod Genet 2013; 30:1239-1244.
102. Hyman JH, Margalioth EJ, Rabinowitz R, et al. DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism. Eur J Obstet Gynecol Reprod Biol 2013; 168:49-53.
103. Narkwichean A, Maalouf W, Campbell BK, Jayaprakasan K. Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol 2013; 11:44.
104. Naasan MN, Harrity C, Pentony L, Mocanu E. Anti-mullerian hormone nomogram in an Irish subfertile population. Ir J Med Sci 2014; 23:.
105. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Reprod Biomed Online 2011; 23:411-420.
106. Li HW, Ng EH, Wong BP, et al. Correlation between three assay systems for anti-mullerian hormone (AMH) determination. J Assist Reprod Genet 2012; 29:1443-1446.
107. Rustamov O, Smith A, Roberts SA, et al. The measurement of anti-mullerian hormone: a critical appraisal. J Clin Endocrinol Metab 2014; 99:723-732. doi: 10.1210/jc.2013-3476.
108. Rustamov O, Smith A, Roberts SA, et al. Anti-mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability. Human Reprod 2012; 27:3085-3091.
109. Zuvela E, Walls M, Matson P. Within-laboratory and between-laboratory variability in the measurement of antimullerian hormone determined within an external quality assurance scheme. Reprod Biol 2013; 13: 255-257.
110. Lukaszuk K, Ludwikowska B, Liss J, et al. Decreasing quality of the new generations of antimullerian hormone assays. BioMed Res Int 2014; 2014:165352.
111. Gassner D, Jung R. First fully automated immunoassay for anti-mullerian hormone. Clin Chem Lab Med 2014.
112. Welsh P, Smith K, Nelson SM. A single-centre evaluation of two new antimullerian hormone assays and comparison with the current clinical standard assay. Hum Reprod 2014; 29:1035-1041
113. Han X, McShane M, Sahertian R, et al. Premixing serum samples with assay buffer is a prerequisite for reproducible anti-mullerian hormone measurement using the Beckman Coulter Gen II assay. Hum Reprod. 2014, 29, 1042-1048.